Alemi and colleagues in a prospective cohort study, found no significant change regarding BP in normotensive patients with type 2 diabetes receiving metformin, glibenclamide + metformin, metformin + insulin or insulin therapy.39 This evidence concerns the gene INS and type 2 diabetes mellitus.